Repair of Topoisomerase I-Mediated DNA Damage

Progress in Nucleic Acid Research and Molecular Biology

Volumn 81, Issue , 2006, Pages 179-229

  Pommier, Yves ^a,b   Barcelo, Juana M ^a,b   Rao, V Ashutosh ^a,b   Sordet, Olivier ^a,b   Jobson, Andrew G ^a,b   Thibaut, Laurent ^a,b   Miao, Ze Hong ^a,b   Seiler, Jennifer A ^a,b   Zhang, Hongliang ^a,b   Marchand, Christophe ^a,b   Agama, Keli ^a,b   Nitiss, John L ^a,b   Redon, Christophe ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE;

ANIMAL; CATALYSIS; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; ENZYME STABILITY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYSIS; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; ENZYME STABILITY; HUMANS;

EID: 33745278845     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(06)81005-6     Document Type: Review

References (265)

1. Wang J.C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell. Biol. 3 (2002) 430-440
2. Zhang H., Barcelo J.M., Lee B., Kohlhagen G., Zimonjic D.B., Popescu N.C., and Pommier Y. Human mitochondrial topoisomerase I. Proc. Natl. Acad. Sci. USA 98 (2001) 10608-10613
3. Zhang H., Meng L.H., Zimonjic D.B., Popescu N.C., and Pommier Y. Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. Nucleic Acids Res. 32 (2004) 2087-2092
4. Hickson I.D. RecQ helicases: Caretakers of the genome. Nat. Rev. Cancer 3 (2003) 169-178
5. Harmon F.G., Brockman J.P., and Kowalczykowski S.C. RecQ helicase stimulates both DNA catenation and changes in DNA topology by topoisomerase III. J. Biol. Chem. 278 (2003) 42668-42678
6. Morham S., Kluckman K.D., Voulomanos N., and Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol. 16 (1996) 6804-6809
7. Zhang C.X., Chen A.D., Gettel N.J., and Hsieh T.S. Essential functions of DNA topoisomerase I in Drosophila melanogaster. Dev. Biol. 222 (2000) 27-40
8. Eng W.K., Faucette L., Johnson R.K., and Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34 (1988) 755-760
9. Baker S.D., Wadkins R.M., Stewart C.F., Beck W.T., and Danks M.K. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry 19 (1995) 134-145
10. Muller M.T., Pfund W.P., Mehta V.B., and Trask D.K. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO. J. 4 (1985) 1237-1243
11. Zhang H., Wang J.C., and Liu L.F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA 85 (1988) 1060-1064
12. Pommier Y., Kohlhagen G., Wu C., and Simmons D.T. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. Biochemistry 37 (1998) 3818-3823
13. Champoux J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
14. Leppard J.B., and Champoux J.J. Human DNA topoisomerase I: Relaxation, roles, and damage control. Chromosoma 114 (2005) 75-85
15. Xu C.-J., Grainge I., Lee J., Harshey R.M., and Jayaram M. Unveiling two distinct ribonuclease activities and a topoisomerase activity in a site-specific DNA recombinase. Mol. Cell 1 (1998) 729-739
16. Pourquier P., Jensen A.D., Gong S.S., Pommier Y., and Rogler C.E. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Res. 27 (1999) 1919-1923
17. Cheng C., and Shuman S. Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks. Mol. Cell. Biol. 20 (2000) 8059-8068
18. Soret J., Gabut M., Dupon C., Kohlhagen G., Stevenin J., Pommier Y., and Tazi J. Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res. 63 (2003) 8203-8211
19. Rossi F., Labourier E., Forne T., Divita G., Derancourt J., Riou J.F., Antoine E., Cathala G., Brunel C., and Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381 (1996) 80-82
20. Stewart L., Redinbo M.R., Qiu X., Hol W.G.J., and Champoux J.J. A model for the mechanism of human topoisomerase I. Science 279 (1998) 1534-1541
21. Lesher D.T., Pommier Y., Stewart L., and Redinbo M.R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Natl. Acad. Sci. USA 99 (2002) 12102-12107
22. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin Jr. A.B., and Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA 99 (2002) 15387-15392
23. Carey J.F., Schultz S.J., Sisson L., Fazzio T.G., and Champoux J.J. DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein. Proc. Natl. Acad. Sci. USA 100 (2003) 5640-5645
24. Woo M.H., Losasso C., Guo H., Pattarello L., Benedetti P., and Bjornsti M.A. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Proc. Natl. Acad. Sci. USA 100 (2003) 13767-13772
25. Koster D.A., Croquette V., Dekker C., Shuman S., and Dekker N.H. Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 434 (2005) 671-674
26. Pommier Y., and Cherfils J. Interfacial protein inhibition: A nature's paradigm for drug discovery. Trends Pharmacol. Sci. 28 (2005) 136-145
27. Pommier Y., and Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem. Anti-Canc. Agents 5 (2005) 421-429
28. Chrencik J.E., Staker B.L., Burgin A.B., Pourquier P., Pommier Y., Stewart L., and Redinbo M.R. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J. Mol. Biol. 339 (2004) 773-784
29. Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., and Burgin A.B. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48 (2005) 2336-2345
30. Ioanoviciu A., Antony S., Pommier Y., Staker B.L., Stewart L., and Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by x-ray crystallographic analysis. J. Med. Chem. 48 (2005) 4803-4814
31. Garcia-Carbonero R., and Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8 (2002) 641-661
32. L.-H. M., Z.-Y. L., and Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr. Topics Med. Chem. 3 (2003) 305-320
33. Covey J.M., Jaxel C., Kohn K.W., and Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49 (1989) 5016-5022
34. Antony S., Jayaraman M., Laco G., Kohlhagen G., Kohn K.W., Cushman M., and Pommier Y. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: Base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 63 (2003) 7428-7435
35. Jaxel C., Capranico G., Kerrigan D., Kohn K.W., and Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 266 (1991) 20418-20423
36. Tanizawa A., Kohn K.W., Kohlhagen G., Leteurtre F., and Pommier Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34 (1995) 7200-7206
37. Pourquier P., and Pommier Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 80 (2001) 189-216
38. Sokhansanj B.A., and Wilson III D.M. Oxidative DNA damage background estimated by a system model of base excision repair. Free Radic. Biol. Med. 37 (2004) 422-427
39. Pourquier P., Ueng L.-M., Fertala J., Wang D., Park H.-J., Essigman J.M., Bjornsti M.-A., and Pommier Y. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. J. Biol. Chem. 274 (1999) 8516-8523
40. Pourquier P., Ueng L.-M., Kohlhagen G., Mazumder A., Gupta M., Kohn K.W., and Pommier Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 272 (1997) 7792-7796
41. Pourquier P., Pilon A., Kohlhagen G., Mazumder A., Sharma A., and Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272 (1997) 26441-26447
42. Sordet O., Khan Q., Kohn K.W., and Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-canc. Agents 3 (2003) 271-290
43. Sordet O., Khan Q.A., Plo I., Pourquier P., Urasaki Y., Yoshida A., Antony S., Kohlhagen G., Solary E., Saparbaev M., Laval J., and Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J. Biol. Chem. 279 (2004) 50499-50504
44. Sordet O., Khan Q.A., and Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle 3 (2004) 1095-1097
45. Sordet O., Liao Z., Liu H., Antony S., Stevens E.V., Kohlhagen G., Fu H., and Pommier Y. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J. Biol. Chem. 279 (2004) 33968-33975
46. Burgin A.B., Huizenga B.N., and Nash H.A. A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucleic Acids Res. 23 (1995) 2973-2979
47. Shuman S. Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli. Proc. Natl. Acad. Sci. USA 86 (1989) 3489-3493
48. Holm C., Covey J.M., Kerrigan D., and Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49 (1989) 6365-6368
49. Hsiang Y.-H., Lihou M.G., and Liu L.F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49 (1989) 5077-5082
50. Stefanis L., Park D.S., Friedman W.J., and Greene L.A. Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J. Neurosci. 19 (1999) 6235-6247
51. Morris E.J., and Geller H.M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity. J. Cell Biol. 134 (1996) 757-770
52. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., and Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 20 (2000) 3977-3987
53. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA-double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278 (2003) 20303-20312
54. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 (1998) 5858-5868
55. Redon C., Pilch D., Rogakou E., Sedelnikova O., Newrock K., and Bonner W. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 12 (2002) 162-169
56. Shao R.-G., Cao C.-X., Zhang H., Kohn K.W., Wold M.S., and Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18 (1999) 1397-1406
57. Shao R.-G., Cao C.-X., Shimizu T., O'Connor P., Kohn K.W., and Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res. 57 (1997) 4029-4035
58. Kohn E.A., Ruth N.D., Brown M.K., Livingstone M., and Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J. Biol. Chem. 277 (2002) 26553-26564
59. Huberman J.A. New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha. Cell 23 (1981) 647-648
60. Horwitz S.B., Chang C.K., and Grollman A.P. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. Mol. Pharmacol. 7 (1971) 632-644
61. Kessel D. Effects of camptothecin on RNA synthesis in leukemia cells. Biochim. Biophys. Acta 246 (1971) 225-232
62. Kann Jr. H.E., and Kohn K.W. Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells. Mol. Pharmacol. 8 (1972) 551-560
63. Collins I., Weber A., and Levens D. Transcriptional consequences of topoisomerase inhibition. Mol. Cell. Biol. 21 (2001) 8437-8451
64. Stewart A.F., Herrera R.E., and Nordheim A. Rapid induction of c-fos transcription reveals quantitive linkage of RNA polymerase II and DNA topoisomerase I enzyme activities. Cell 60 (1990) 141-146
65. Zhou Y., Gwadry F.G., Reinhold W.C., Miller L.D., Smith L.H., Scherf U., Liu E.T., Kohn K.W., Pommier Y., and Weinstein J.N. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects. Cancer Res. 62 (2002) 1688-1695
66. Daoud S.S., Munson P.J., Reinhold W., Young L., Prabhu V., Yu Q., LaRose J., Kohn K.W., Weinstein J.N., and Pommier Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in Human colon carcinoma cells: A pharmacogenomic study. Cancer Res. 63 (2003) 2782-2793
67. Ljungman M., and Hanawalt P.C. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 17 (1996) 31-35
68. Bendixen C., Thomsen B., Alsner J., and Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 29 (1990) 5613-5619
69. Wu J., and Liu L.F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 25 (1997) 4181-4186
70. Mondal N., and Parvin J.D. DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Nature 413 (2001) 435-438
71. Duann P., Sun M., Lin C.T., Zhang H., and Liu L.F. Plasmid linking number change induced by topoisomerase I-mediated DNA damage. Nucleic Acids Res. 27 (1999) 2905-2911
72. Sun M., Duann P., Lin C.T., Zhang H., and Liu L.F. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage. Ann. N. Y. Acad. Sci. 922 (2000) 340-342
73. Merino A., Madden K.R., Lane W.S., Champoux J.J., and Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365 (1993) 227-232
74. Shykind B.M., Kim J., Stewart L., Champoux J.J., and Sharp P.A. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 11 (1997) 397-407
75. Desai S.D., Zhang H., Rodriguez-Bauman A., Yang J.M., Wu X., Gounder M.K., Rubin E.H., and Liu L.F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol. 23 (2003) 2341-2350
76. Squires S., Ryan A.J., Strutt H.L., and Johnson R.T. Hypersensitivity of Cockayne's syndrome cells to camptothecins is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 53 (1993) 2012-2019
77. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., and Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61 (2001) 5926-5932
78. Pommier Y., Redon C., Rao A., Seiler J.A., Sordet O., Takemura H., Antony S., Meng L.-H., Liao Z.Y., Kohlhagen G., Zhang H., and Kohn K.W. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res. 532 (2003) 173-203
79. Rao A., Fan A.M., Meng L., Doe C.L., North P.S., Hickson I., and Pommier Y. Phosphorylation of BLM, dissociation for topoisomerase IIIα and colocalization with γ-H2AX after topoisomerase I-induced replication damage. Mol. Cell. Biol. 25 (2005) 8925-8937
80. Wu L., and Hickson I.D. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature 426 (2003) 870-874
81. Bjergbaek L., Cobb J.A., Tsai-Pflugfelder M., and Gasser S.M. Mechanistically distinct roles for Sgs1p in checkpoint activation and replication fork maintenance. EMBO J. 24 (2005) 405-417
82. Imamura O., Fujita K., Itoh C., Takeda S., Furuichi Y., and Matsumoto T. Werner and Bloom helicases are involved in DNA repair in a complementary fashion. Oncogene 21 (2002) 954-963
83. Boom V., Jaspers N.G., and Vermeulen W. When machines get stuck-obstructed RNA polymerase II: Displacement, degradation or suicide. Bioessays 24 (2002) 780-784
84. Pommier Y., Jenkins J., Kohlhagen G., and Leteurtre F. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutat. Res. 337 (1995) 135-145
85. Huang C.C., Han C.S., Yue X.F., Shen C.M., Wang S.W., Wu F.G., and Xu B. Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. J. Natl. Cancer Inst. 71 (1983) 841-847
86. Pinero J., Baena M., Ortiz T., and Cortes F. Sister chromatid exchange induced by DNA topoisomerases poisons in late replicating heterochromatin: Influence of inhibition of replication and transcription. Mutat. Res. 354 (1996) 195-201
87. Fasullo M., Zeng L., and Giallanza P. Enhanced stimulation of chromosomal translocations by radiomimetic DNA damaging agents and camptothecin in Saccharomyces cerevisiae rad9 checkpoint mutants. Mutat. Res. 547 (2004) 123-132
88. Pouliot J.J., Yao K.C., Robertson C.A., and Nash H.A. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topo I covalent complexes. Science 286 (1999) 552-555
89. Yang S.-W., Burgin A.B., Huizenga B.N., Robertson C.A., Yao K.C., and Nash H.A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc. Natl. Acad. Sci. USA 93 (1996) 11534-11539
90. Interthal H., Pouliot J.J., and Champoux J.J. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc. Natl. Acad. Sci. USA 98 (2001) 12009-12014
91. Takashima H., Boerkoel C.F., John J., Saifi G.M., Salih M.A., Armstrong D., Mao Y., Quiocho F.A., Roa B.B., Nakagawa M., Stockton D.W., and Lupski J.R. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat. Genet. 32 (2002) 267-272
92. Barthelmes H.U., Grue P., Feineis S., Straub T., and Boege F. Active DNA topoisomerase IIalpha is a component of the salt-stable centrosome core. J. Biol. Chem. 275 (2000) 38823-38830
93. Nivens M.C., Felder T., Galloway A.H., Pena M.M., Pouliot J.J., and Spencer H.T. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase. Cancer Chemother. Pharmacol. 53 (2004) 107-115
94. Interthal H., Chen H.J., Khel-Fie T.E., Zotzmann J., Leppard J.B., and Champoux J.J. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 24 (2005) 2224-2233
95. Zhou T., Lee J.W., Tatavarthi H., Lupski J.R., Valerie K., and Povirk L.F. Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res. 33 (2005) 289-297
96. Pouliot J.J., Robertson C.A., and Nash H.A. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 6 (2001) 677-687
97. Liu C., Pouliot J.J., and Nash H.A. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc. Natl. Acad. Sci. USA 99 (2002) 14970-14975
98. Vance J.R., and Wilson T.E. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc. Natl. Acad. Sci. USA 99 (2002) 13669-13674
99. Deng C., Brown J.A., You D., and Brown J.M. Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics 170 (2005) 591-600
100. Inamdar K.V., Pouliot J.J., Zhou T., Lees-Miller S.P., Rasouli-Nia A., and Povirk L.F. Conversion of phosphoglycolate to phosphate termini on 3′ overhangs of DNA double-strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J. Biol. Chem. 277 (2002) 27162-27168
101. Davies D.R., Interthal H., Champoux J.J., and Hol W.G. The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (Camb.) 10 (2002) 237-248
102. Davies D.R., Interthal H., Champoux J.J., and Hol W.G. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J. Mol. Biol. 324 (2002) 917-932
103. Davies D.R., Interthal H., Champoux J.J., and Hol W.G. Crystal structure of a transition state mimic for tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem. Biol. 10 (2003) 139-147
104. Stuckey J.A., and Dixon J.E. Crystal structure of a phospholipase D family member. Nat. Struct. Biol. 6 (1999) 278-284
105. Interthal H., Chen H.J., and Champoux J.J. Human Tdp1 cleaves a broad spectrum of substrates including phosphoamide linkages. J. Biol. Chem. 280 (2005) 36518-36528
106. Debethune L., Kohlhagen G., Grandas A., and Pommier Y. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res. 30 (2002) 1198-1204
107. Beidler D.R., Chang J.-Y., Zhou B.-S., and Cheng Y.-C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res. 56 (1995) 345
108. Desai S.D., Liu L.F., Vazquez-Abad D., and D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272 (1997) 24159-24164
109. Raymond A.C., Staker B.L., and Burgin Jr. A.B. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1). J. Biol. Chem. 280 (2005) 22029-22035
110. Vance J.R., and Wilson T.E. Uncoupling of 3′-phosphatase and 5′-kinase functions in budding yeast. Characterization of Saccharomyces cerevisiae DNA 3′-phosphatase (TPP1). J. Biol. Chem. 276 (2001) 15073-15081
111. Vance J.R., and Wilson T.E. Repair of DNA strand breaks by the overlapping functions of lesion-specific and non-lesion-specific DNA 3′ phosphatases. Mol. Cell. Biol. 21 (2001) 7191-7198
112. Meijer M., Karimi-Busheri F., Huang T.Y., Weinfeld M., and Young D. Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe. J. Biol. Chem. 277 (2002) 4050-4055
113. Karimi-Busheri F., Daly G., Robins P., Canas B., Pappin D.J.C., Sgouros J., Miller G.G., Fakhrai H., Davis E.M., Beau M.M., and Weinfeld M. Molecular Characterization of a Human DNA Kinase. J. Biol. Chem. 274 (1999) 24187-24194
114. Jilani A., Ramotar D., Slack C., Ong C., Yang X.M., Scherer S.W., and Lasko D.D. Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3′-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage. J. Biol. Chem. 274 (1999) 24176-24186
115. Rasouli-Nia A., Karimi-Busheri F., and Weinfeld M. Stable down-regulation of human polynucleotide kinase enhances spontaneous mutation frequency and sensitizes cells to genotoxic agents. Proc. Natl. Acad. Sci. USA 101 (2004) 6905-6910
116. Plo I., Liao Z.Y., Barcelo J.M., Kohlhagen G., Caldecott K.W., Weinfeld M., and Pommier Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst.) 2 (2003) 1087-1100
117. El-Khamisy S.F., Saifi G.M., Weinfeld M., Johansson F., Helleday T., Lupski J.R., and Caldecott K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434 (2005) 108-113
118. Chatterjee S., Cheng M.-F., Trivedi D., Petzold S.J., and Berger N.A. Camptothecin hypersensitivity in poly (adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1 (1989) 389-394
119. Clements P.M., Breslin C., Deeks E.D., Byrd P.J., Ju L., Bieganowski P., Brenner C., Moreira M.C., Taylor A.M., and Caldecott K.W. The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4. DNA Repair (Amst.) 3 (2004) 1493-1502
120. Moreira M.C., Barbot C., Tachi N., Kozuka N., Uchida E., Gibson T., Mendonca P., Costa M., Barros J., Yanagisawa T., Watanabe M., Ikeda Y., et al. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat. Genet. 29 (2001) 189-193
121. Paulson H.L., and Miller V.M. Breaks in coordination: DNA repair in inherited ataxia. Neuron 46 (2005) 845-848
122. Mosesso P., Piane M., Palitti F., Pepe G., Penna S., and Chessa L. The novel human gene aprataxin is directly involved in DNA single-strand-break repair. Cell. Mol. Life Sci. 62 (2005) 485-491
123. Cheng T.J., Rey P.G., Poon T., and Kan C.C. Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway. Eur. J. Biochem. 269 (2002) 3697-3704
124. Rideout M.C., Raymond A.C., and Burgin Jr. A.B. Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. Nucleic Acids Res. 32 (2004) 4657-4664
125. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
126. Bastine-Shanower S.A., Fricke W.M., Mullen J.R., and Brill S.J. The mechanism of mus81-mms4 cleavage site selection distinguishes it from the homologous endonuclease rad1-rad10. Mol. Cell. Biol. 23 (2003) 3487-3496
127. Mullen J.R., Kaliraman V., Ibrahim S.S., and Brill S.J. Requirement for three novel protein complexes in the absence of the Sgs1 DNA helicase in Saccharomyces cerevisiae. Genetics 157 (2001) 103-118
128. Fricke W.M., and Brill S.J. Slx1-Slx4 is a second structure-specific endonuclease functionally redundant with Sgs1-Top3. Genes Dev. 17 (2003) 1768-1778
129. Doe C.L., Ahn J.S., Dixon J., and Whitby M.C. Mus81-Eme1 and Rqh1 involvement in processing stalled and collapsed replication forks. J. Biol. Chem. 277 (2002) 32753-32759
130. Ciccia A., Constantinou A., and West S.C. Identification and characterization of the human Mus81/Eme1 endonuclease. J. Biol. Chem. 278 (2003) 25172-25178
131. Bennett C.B., Lewis L.K., Karthikeyan G., Lobachev K.S., Jin Y.H., Sterling J.F., Snipe J.R., and Resnick M.A. Genes required for ionizing radiation resistance in yeast. Nat. Genet. 29 (2001) 426-434
132. D'Amours D., and Jackson S.P. The Mre11 complex: At the crossroads of DNA repair and checkpoint signalling. Nat. Rev. Mol. Cell. Biol. 3 (2002) 317-327
133. Zheng L., Zhou M., Chai Q., Parrish J., Xue D., Patrick S.M., Turchi J.J., Yannone S.M., Chen D., and Shen B. Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Rep. 6 (2005) 83-89
134. Reid R.J., Fiorani P., Sugawara M., and Bjornsti M.A. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl. Acad. Sci. USA 96 (1999) 11440-11445
135. Fiorani P., Reid R.J., Schepis A., Jacquiau H.R., Guo H., Thimmaiah P., Benedetti P., and Bjornsti M.A. The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons. J. Biol. Chem. 279 (2004) 21271-21281
136. Jacquiau H.R., Waardenburg R.C., Reid R.J., Woo M.H., Guo H., Johnson E.S., and Bjornsti M.A. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage. J. Biol. Chem. 280 (2005) 23566-23575
137. Dendouga N., Gao H., Moechars D., Janicot M., Vialard J., and McGowan C.H. Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol. Cell. Biol. 25 (2005) 7569-7579
138. Nelson W.G., and Kastan M.B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14 (1994) 1815-1823
139. Kohn K.W., and Pommier Y. Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage. Biochem. Biophys. Res. Commun. 331 (2005) 816-827
140. Chen Y., and Sanchez Y. Chk1 in the DNA damage response: Conserved roles from yeasts to mammals. DNA Repair (Amst.) 3 (2004) 1025-1032
141. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 893-897
142. Ljungman M. Activation of DNA damage signaling. Mutat. Res. 577 (2005) 203-216
143. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carttini-Rivera S., DeMayo F., Bradley A., Donehower L.A., and Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 14 (2000) 1448-1459
144. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., Ikeda K., Nakayama K., and Nakanishi M. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev. 14 (2000) 1439-1447
145. Zachos G., Rainey M.D., and Gillespie D.A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 22 (2003) 713-723
146. Garvik B., Carson M., and Hartwell L. Single-stranded DNA arising at telomeres in cdc13 mutants may constitute a specific signal for the RAD9 checkpoint. Mol. Cell. Biol. 15 (1995) 6128-6138
147. Sanchez Y., Bachant J., Wang H., Hu F., Liu D., Tetzlaff M., and Elledge S.J. Control of the DNA damage checkpoint by chk1 and rad53 protein kinases through distinct mechanisms. Science 286 (1999) 1166-1171
148. Chini C.C., and Chen J. Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst.) 3 (2004) 1033-1037
149. Sorensen C.S., Syljuasen R.G., Lukas J., and Bartek J. ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage. Cell Cycle 3 (2004) 941-945
150. Gottifredi V., and Prives C. The S phase checkpoint: When the crowd meets at the fork. Semin. Cell. Dev. Biol. 16 (2005) 355-368
151. Gatei M., Sloper K., Sorensen C., Syljuasen R., Falck J., Hobson K., Savage K., Lukas J., Zhou B.B., Bartek J., and Khanna K.K. ATM and NBS1 dependent phosphorylation of CHK1 on S317 in response to IR. J. Biol. Chem. 278 (2003) 14806-14811
152. Bartek J., and Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3 (2003) 421-429
153. Guerra B., Issinger O.G., and Wang J.Y. Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2. Oncogene 22 (2003) 4933-4942
154. Shtivelman E., Sussman J., and Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr. Biol. 12 (2002) 919-924
155. Wan S., Capasso H., and Walworth N.C. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast. Yeast 15 (1999) 821-828
156. Tsao Y.-P., D'Arpa P., and Liu L.F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc2/cyclin B. Cancer Res. 52 (1992) 1823-1829
157. Wan S., and Walworth N.C. A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1. Curr. Genet. 38 (2001) 299-306
158. Dunaway S., Liu H.Y., and Walworth N.C. Interaction of 14-3-3 protein with Chk1 affects localization and checkpoint function. J. Cell. Sci. 118 (2005) 39-50
159. Chen L., Liu T.-H., and Walworth N.C. Association of Chk1 with 14.3.3 proteins is stimulated by DNA damage. Genes Dev. 13 (1999) 675-685
160. Capasso H., Palermo C., Wan S., Rao H., John U.P., O'Connell M.J., and Walworth N.C. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J. Cell. Sci. 115 (2002) 4555-4564
161. Yin M.B., Hapke G., Wu J., Azrak R.G., Frank C., Wrzosek C., and Rustum Y.M. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem. Biophys. Res. Commun. 295 (2002) 435-444
162. Flatten K., Dai N.T., Vroman B.T., Loegering D., Erlichman C., Karnitz L.M., and Kaufmann S.H. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J. Biol. Chem. 280 (2005) 14349-14355
163. Cliby W.A., Lewis K.A., Lilly K.K., and Kaufmann S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277 (2002) 1599-1606
164. Hapke G., Yin M.B., Wu J., Frank C., and Rustum Y.M. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38. Int. J. Oncol. 21 (2002) 1059-1066
165. Wang J.L., Wang X., Wang H., Iliakis G., and Wang Y. CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity. Cell Cycle 1 (2002) 267-272
166. Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S., and Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 278 (2003) 21767-21773
167. Sorensen C.S., Hansen L.T., Dziegielewski J., Syljuasen R.G., Lundin C., Bartek J., and Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell. Biol. 7 (2005) 195-201
168. Zhang Y.W., Otterness D.M., Chiang G.G., Xie W., Liu Y.C., Mercurio F., and Abraham R.T. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell 19 (2005) 607-618
169. Nomura M., Nomura N., and Yamashita J. Geldanamycin-induced degradation of Chk1 is mediated by proteasome. Biochem. Biophys. Res. Commun. 335 (2005) 900-905
170. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., and Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24 (2005) 1403-1411
171. Levesque A.A., Kohn E.A., Bresnick E., and Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 24 (2005) 3786-3796
172. Tse A.N., and Schwartz G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 64 (2004) 6635-6644
173. Pommier Y., Sordet O., Rao A., Zhang H., and Kohn K.W. Targeting Chk2 kinase: Molecular interaction maps and therapeutic rationale. Curr. Pharm. Des. 11 (2005) 2855-2872
174. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., and Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287 (2000) 1824-1827
175. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., Anderson C.W., Appella E., Nakanishi M., Suzuki H., Nagashima K., Sawa H., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21 (2002) 5195-5205
176. Ahn J., Urist M., and Prives C. The Chk2 protein kinase. DNA Repair (Amst.) 3 (2004) 1039-1047
177. Ahn J.-Y., Schwartz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
178. Helt C.E., Cliby W.A., Keng P.C., Bambara R.A., and O'Reilly M.A. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J. Biol. Chem. 280 (2005) 1186-1192
179. Li J., and Stern D.F. Regulation of CHK2 by DNA-dependent protein kinase. J. Biol. Chem. 280 (2005) 12041-12050
180. Bahassi E.M., Conn C.W., Myer D.L., Hennigan R.F., McGowan C.H., Sanchez Y., and Stambrook P.J. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 21 (2002) 6633-6640
181. Myer D.L., Bahassi el M., and Stambrook P.J. The Plk3-Cdc25 circuit. Oncogene 24 (2005) 299-305
182. Tsvetkov L., and Stern D.F. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. Cell Cycle 4 (2005) 166-171
183. Tsvetkov L., Xu X., Li J., and Stern D.F. Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J. Biol. Chem. 278 (2003) 8468-8475
184. Tsvetkov L.M., Tsekova R.T., Xu X., and Stern D.F. The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2. Cell Cycle 4 (2005) 609-617
185. Wei J.H., Chou Y.F., Ou Y.H., Yeh Y.H., Tyan S.W., Sun T.P., Shen C.Y., and Shieh S.Y. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. J. Biol. Chem. 280 (2005) 7748-7757
186. Ahn J.Y., Li X., Davis H.L., and Canman C.E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 277 (2002) 19389-19395
187. Schwarz J.K., Lovly C.M., and Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 1 (2003) 598-609
188. Yu Q., Rose J.H., Zhang H., and Pommier Y. Inhibition of Chk2 activity and radiation-induced p53 elevation by the cell cycle checkpoint abrogator 7-hydroxystaurosporine (UCN-01). Proc. Am. Assoc. Cancer Res. 42 (2001) 800
189. Keramaris E., Hirao A., Slack R.S., Mak T.W., and Park D.S. Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage. J. Biol. Chem. 278 (2003) 37782-37789
190. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., Zhang X., Annan R.S., Lu Q., Faucette L.F., Scott G.F., Li X., et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18 (1999) 4047-4054
191. Ward I.M., and Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem. 276 (2001) 47759-47762
192. Agner J., Falck J., Lukas J., and Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp. Cell. Res. 302 (2005) 162-169
193. Wang X., Khadpe J., Hu B., Iliakis G., and Wang Y. An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells. J. Biol. Chem. 278 (2003) 30869-30874
194. Goulaouic H., Roulon T., Flamand O., Grondard L., Lavelle F., and Riou J.-F. Purification and characterization of human DNA topoisomerase IIIα. Nucleic Acids Res. 27 (1999) 2443-2450
195. Rosenthal D.S., Simbulan-Rosenthal C.M., Liu W.F., Velena A., Anderson D., Benton B., Wang Z.Q., Smith W., Ray R., and Smulson M.E. PARP determines the mode of cell death in skin fibroblasts, but not keratinocytes, exposed to sulfur mustard. J. Invest. Dermatol. 117 (2001) 1566-1573
196. Pommier Y., Pourquier P., Fan Y., and Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400 (1998) 83-105
197. Pourquier P., Takebayashi Y., Urasaki Y., Gioffre C., Kohlhagen G., and Pommier Y. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (Ara-C) in vitro and in ara-C-treated cells. Proc. Natl. Acad. Sci. USA 97 (2000) 1885-1890
198. Chrencik J.E., Burgin A.B., Pommier Y., Stewart L., and Redinbo M.R. Structural impact of the leukemia drug Ara-C on the covalent human topoisomerase I DNA complex. J. Biol. Chem. 278 (2003) 12461-12466
199. Pourquier P., Gioffre C., Kohlhagen G., Urasaki Y., Goldwasser F., Hertel L.W., Yu S., Pon R.T., Gmeiner W.H., and Pommier Y. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin. Cancer Res. 8 (2002) 2499-2504
200. Leteurtre F., Kohlhagen G., Fesen M.R., Tanizawa A., Kohn K.W., and Pommier Y. Effects of DNA methylation on topoisomerase I and II cleavage activities. J. Biol. Chem. 269 (1994) 7893-7900
201. Antony S., Arimondo P.B., Sun J.S., and Pommier Y. Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures. Nucleic Acids Res. 32 (2004) 5163-5173
202. Lanza A., Tornatelli S., Rodolfo C., Scanavini M.C., and Pedrini A.M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 271 (1996) 6978-6986
203. Subramanian D., Rosenstein B.S., and Muller M.T. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: Possible relationship with DNA repair. Cancer Res. 58 (1998) 976-984
204. 6-methylguanine. Cancer Res. 61 (2001) 53-58
205. Pommier Y., Laco G.S., Kohlhagen G., Sayer J.M., Kroth H., and Jerina D.M. Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]-pyrene diol epoxide adducts at the 6-amino group of adenine. Proc. Natl. Acad. Sci. USA 97 (2000) 10739-10744
206. Pommier Y., Kohlhagen G., Pourquier P., Sayer J.M., Kroth H., and Jerina D.M. Benzo[a]pyrene epoxide adducts in DNA are potent inhibitors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proc. Natl. Acad. Sci. USA 97 (2000) 2040-2045
207. Pommier Y., Kohlhagen G., Laco G.S., Kroth H., Sayer J.M., and Jerina D.M. Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem. 277 (2002) 13666-13672
208. Pourquier P., Bjornsti M.-A., and Pommier Y. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1, N6-ethenoadenine. J. Biol. Chem. 273 (1998) 27245-27249
209. Antony S., Theruvathu J.A., Brooks P.J., Lesher D.T., Redinbo M., and Pommier Y. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2′-deoxyguanosine. Nucleic Acids Res. 32 (2004) 5685-5692
210. Moser B.A., Brondello J.M., Baber-Furnari B., and Russell P. Mechanism of caffeine-induced checkpoint override in fission yeast. Mol. Cell. Biol. 20 (2000) 4288-4294
211. Smith P.J., Makinson T.A., and Watson J.V. Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol. 55 (1989) 217-231
212. Johnson M.A., and Jones N.J. The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: Two new complementation groups of etoposide sensitive mutants. Mutation Res. 435 (1999) 271-282
213. Jones N.J., Ellard S., Waters R., and Parry E.M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: Phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. Carcinogenesis 14 (1993) 2487-2494
214. Johnson M.A., Bryant P.E., and Jones N.J. Isolation of camptothecin-sensitive Chinese hamster cell mutants: Phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group. Mutagenesis 15 (2000) 367-374
215. Walton M.I., Whysong D., O'Connor P.M., Hockenbery D., Korsmeyer S.J., and Kohn K.W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53 (1993) 1853-1861
216. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
217. Rahden-Staron I.I., Szumilo M., Grosicka E., Zwet M., and Zdzienicka M.Z. Defective Brca2 influences topoisomerase I activity in mammalian cells. Acta Biochim. Pol. 50 (2003) 139-144
218. Yu Q., Rose J.H., Zhang H., and Pommier Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505 (2001) 7-12
219. Hinz J.M., Helleday T., and Meuth M. Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3. Carcinogenesis 24 (2003) 249-253
220. Culmsee C., Bondada S., and Mattson M.P. Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity. Brain Res. Mol. Brain Res. 87 (2001) 257-262
221. Zwet M., Overkamp W.J., Friedl A.A., Klein B., Verhaegh G.W., Jaspers N.G., Midro A.T., Eckardt-Schupp F., Lohman P.H., and Zdzienicka M.Z. Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. Mutat. Res. 434 (1999) 17-27
222. Chatterjee S., Cheng M.F., and Berger N.A. Hypersensitivity to clinically useful alkylating agents and radiations in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2 (1990) 401-407
223. Godthelp B.C., Wiegant W.W., van Duijn-Goedhart A., Scharer O.D., Buul P.P., Kanaar R., and Zdzienicka M.Z. Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res. 30 (2002) 2172-2182
224. Barthelmes H.U., Habermeyer M., Christensen M.O., Mielke C., Interthal H., Pouliot J.J., Boege F., and Marko D. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J. Biol. Chem. 279 (2004) 55618-55625
225. Gupta M., Fan S., Zhan Q., Kohn K.W., O'Connor P.M., and Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 3 (1997) 1653-1660
226. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P., and Wyche J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277 (2002) 17154-17160
227. Lebel M., and Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of proliferative capacity. Proc. Natl. Acad. Sci. USA 95 (1998) 13097-13102
228. Poot M., Gollahon K.A., and Rabinovitch P.S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 104 (1999) 10-14
229. Pichierri P., Franchitto A., Mosesso P., and Palitti F. Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. Mutat. Res. 456 (2000) 45-57
230. Caldecott K., and Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res. 255 (1991) 111-121
231. Barrows L.R., Holden J.A., Anderson M., and D'Arpa P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res. 408 (1998) 103-110
232. Park S.Y., Lam W., and Cheng Y.C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62 (2002) 459-465
233. Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H., Gatti R., Date H., Onodera O., Taucher-Scholz G., and Lavin M.F. Aprataxin, a novel protein that protects against genotoxic stress. Hum. Mol. Genet. 13 (2004) 1081-1093
234. Thacker J., and Ganesh A.N. DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: Comparisons to ataxia-telangiectasia cells. Mutat. Res. 235 (1990) 49-58
235. Nitiss J., and Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA 85 (1988) 7501-7505
236. Simon J.A., Szankasi P., Nguyen D.K., Ludlow C., Dunstan H.M., Roberts C.J., Jensen E.L., Hartwell L.H., and Friend S.H. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60 (2000) 328-333
237. Redon C., Pilch D., Rogakou E., Orr A.H., Lowndes N.F., and Bonner W.M. Yeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damage. EMBO Rep. 4 (2003) 1-7
238. Hryciw T., Tang M., Fontanie T., and Xiao W. MMS1 protects against replication-dependent DNA damage in Saccharomyces cerevisiae. Mol. Genet. Genomics 266 (2002) 848-857
239. Zhang H., and Siede W. Validation of a novel assay for checkpoint responses: Characterization of camptothecin derivatives in Saccharomyces cerevisiae. Mutat. Res. 527 (2003) 37-48
240. Walowsky C., Fitzhugh D.J., Castaño I.B., Ju J.Y., Levin N.A., and Christman M.F. The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin. J. Biol. Chem. 274 (1999) 7302-7308
241. Scheller J., Schurer A., Rudolph C., Hettwer S., and Kramer W. MPH1, a yeast gene encoding a DEAH protein, plays a role in protection of the genome from spontaneous and chemically induced damage. Genetics 155 (2000) 1069-1081
242. Redon C., Pilch D.R., and Bonner W.M. Genetic analysis of Saccharomyces cerevisiae H2A serine 129 mutant suggests a functional relationship between H2A and the sister chromatid cohesion partners Csm3-Tof1 for the repair of topoisomerase I-induced DNA damage. Genetics 172 (2006) 67-76
243. Bird A.W., Yu D.Y., Pray-Grant M.G., Qiu Q., Harmon K.E., Megee P.C., Grant P.A., Smith M.M., and Christman M.F. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 419 (2002) 411-415
244. Choy J.S., and Kron S.J. NuA4 subunit Yng2 function in intra-S-phase DNA damage response. Mol. Cell. Biol. 22 (2002) 8215-8225
245. Lewis L.K., Karthikeyan G., Cassiano J., and Resnick M.A. Reduction of nucleosome assembly during new DNA synthesis impairs both major pathways of double-strand break repair. Nucleic Acids Res. 33 (2005) 4928-4939
246. Fiorani P., and Bjornsti M.A. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. N. Y. Acad. Sci. 922 (2000) 65-75
247. Doe C.L., and Whitby M.C. The involvement of Srs2 in post-replication repair and homologous recombination in fission yeast. Nucleic Acids Res. 32 (2004) 1480-1491
248. Doe C.L., Osman F., Dixon J., and Whitby M.C. DNA repair by a Rad22-Mus81-dependent pathway that is independent of Rhp51. Nucleic Acids Res. 32 (2004) 5570-5581
249. Collura A., Blaisonneau J., Baldacci G., and Francesconi S. The fission yeast Crb2/Chk1 pathway coordinates the DNA damage and spindle checkpoint in response to replication stress induced by topoisomerase I inhibitor. Mol. Cell. Biol. 25 (2005) 7889-7899
250. Dalgaard J.Z., and Klar A.J. swi1 and swi3 perform imprinting, pausing, and termination of DNA replication in S. pombe. Cell 102 (2000) 745-751
251. Nitiss J.L., Nitiss K.C., Rose A., and Waltman J.L. Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage. J. Biol. Chem. 276 (2001) 26708-26714
252. Kim J., Robertson K., Mylonas K.J.L., Gray F.C., Charapitsa I., and MacNeill S.A. Contrasting effects of Elg1-RFC and Ctf18-RFC inactivation in the absence of fully functional RFC in fission yeast. Nucleic Acids Res. 33 (2005) 4078-4089
253. Westmoreland T.J., Marks J.R., Olson Jr. J.A., Thompson E.M., Resnick M.A., and Bennet C.B. Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryot. Cell 3 (2004) 430-446
254. Malik M., and Nitiss J.L. DNA repair functions that control sensitivity to topoisomerase-targeting drugs. Eukaryot. Cell 3 (2004) 82-90
255. Khasanov F.K., Salakhova A.F., Chepurnaja O.V., Korolev V.G., and Bashkirov V.I. Identification and characterization of the rlp1+, the novel Rad51 paralog in the fission yeast Schizosaccharomyces pombe. DNA Repair (Amst) 3 (2004) 1363-1374
256. Lambert S., Mason S.J., Barber L.J., Hartley J.A., Pearce J.A., Carr A.M., and McHugh P.J. Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links. Mol. Cell. Biol. 23 (2003) 4728-4737
257. Yoshida S.H., Al-Amodi H., Nakamura T., McInerny C.J., and Shimoda C. The Schizosaccharomyces pombe cdt2(+) gene, a target of G1-S phase-specific transcription factor complex DSC1, is required for mitotic and premeiotic DNA replication. Genetics 164 (2003) 881-893
258. Parsons A.B., Brost R.L., Ding H., Li Z., Zhang C., Sheikh B., Brown G.W., Kane P.M., Hughes T.R., and Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22 (2004) 62-69
259. Rouse J. Esc4p, a new target of Mec1p (ATR), promotes resumption of DNA synthesis after DNA damage. EMBO J. 23 (2004) 1188-1197
260. Masumoto H., Hawke D., Kobayashi R., and Verreault A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436 (2005) 294-298
261. Liu C., Poitelea M., Watson A., Yoshida S.H., Shimoda C., Holmberg C., Nielsen O., and Carr A.M. Transactivation of Schizosaccharomyces pombe cdt2+ stimulates a Pcu4-Ddb1-CSN ubiquitin ligase. EMBO J. 24 (2005) 3940-3951
262. Nitiss K.C., Malik M., He X., White S.W., and Nitiss J.L. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc. Natl. Acad. Sci. USA 103 (2006) 8953-8958
263. Pommier Y., Weinstein J.N., Aladjem M.I., and Kohn M. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 12 (2006) 2657-2661
264. Torres J.Z., Schnakenberg S.L., and Zakian V.A. Saccharomyces cerevisiae Rrm3p DNA helicase promotes genome integrity by preventing replication fork stalling: Viability of rrm3 cells requires the intra-S-phase checkpoint and fork restart activities. Mol. Cell. Biol. 24 (2004) 3198-3212
265. Sanders S.L., Portoso M., Mata J., Bahler J., Allshire R.C., and Kouzarides T. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 119 (2004) 603-614